RamyAlyMahmoudMDMPH
Preventive Medicine • Yardley, PAAerospace Medicine, Public Health & General Preventive Medicine
CEO, Optinose (NASDAQ: OPTN)
Dr. Mahmoud is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1020 Stony Hill Rd Ste 300
Yardley, PA 19067Phone+1 609-462-7216
Education & Training
National Capital Consortium Public Health and General Preventive MedicineResidency, Public Health and General Preventive Medicine, 1992 - 1994
Harvard School of Public HealthMPH, Health Policy & Management, 1992 - 1993
Harvard Medical SchoolFellowship, Clinical Effectiveness, 1992 - 1992
United States Army School of Aviation MedicineFS, 1991 - 1991- National Capital ConsortiumResidency, Internal Medicine, 1987 - 1990
University of Miami Leonard M. Miller School of MedicineClass of 1987
Certifications & Licensure
PA State Medical License 1997 - 2024
FL State Medical License 1990 - 2000
VA State Medical License 1990 - 1994
LA State Medical License 1987 - 1990- American Board of Internal Medicine Internal Medicine
- American Board of Preventive Medicine Public Health & General Preventive Medicine
Publications & Presentations
PubMed
- 92 citationsRisperidone for treatment-refractory major depressive disorder: a randomized trial.Ramy A. Mahmoud, Gahan Pandina, Ibrahim Turkoz, Colette Kosik-Gonzalez, Carla M. Canuso
Annals of Internal Medicine. 2007-11-06 - 57 citationsRisperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychoticsSanford I. Finkel, Chris M. Kozma, Long Stacey Todd, Andrew Greenspan, Ramy A. Mahmoud
International Psychogeriatrics. 2005-12-01 - 28 citationsAntipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004).William DuMouchel, David Fram, Xionghu Yang, Ramy A. Mahmoud, Amy L Grogg
Annals of Clinical Psychiatry. 2008-01-01
Press Mentions
Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCEMay 4th, 2023- Optinose Submits Supplemental New Drug Application for XHANCE Label ExpansionFebruary 21st, 2023
- Investors Gain a Breath of Fresh Air from Ph. 3 CS Trial ResultsJune 14th, 2022
- Join now to see all
Professional Memberships
- Fellow
- Member
- Member
- Association of Military Surgeons of the United StatesMember
- International Society for CNS Clinical Trials and MethodologyFounding Member, Past President
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
